Antimicrobial blue light: A ‘Magic Bullet’ for the 21st century and beyond?

[Display omitted] Over the past decade, antimicrobial blue light (aBL) at 400 − 470 nm wavelength has demonstrated immense promise as an alternative approach for the treatment of multidrug-resistant infections. Since our last review was published in 2017, there have been numerous studies that have i...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2022-01, Vol.180, p.114057-114057, Article 114057
Main Authors: Leanse, Leon G., dos Anjos, Carolina, Mushtaq, Sana, Dai, Tianhong
Format: Article
Language:English
Subjects:
Animals
Antimicrobial blue light
Antimicrobial resistance
Antimicrobial synergism
Drug Resistance, Microbial
Drug Resistance, Multiple
Humans
Infections - microbiology
Infections - therapy
Infectious diseases
Microbes
Photolysis
Phototherapy - adverse effects
Phototherapy - methods
Phototherapy - trends
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Over the past decade, antimicrobial blue light (aBL) at 400 − 470 nm wavelength has demonstrated immense promise as an alternative approach for the treatment of multidrug-resistant infections. Since our last review was published in 2017, there have been numerous studies that have investigated aBL in terms of its, efficacy, safety, mechanism, and propensity for resistance development. In addition, researchers have looked at combinatorial approaches that exploit aBL and other traditional and non-traditional therapeutics. To that end, this review aims to update the findings from numerous studies that capitalize on the antimicrobial effects of aBL, with a focus on: efficacy of aBL against different microbes, identifying endogenous chromophores and targets of aBL, Resistance development to aBL, Safety of aBL against host cells, and Synergism of aBL with other agents. We will also discuss our perspective on the future of aBL.
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2021.114057